NASDAQ:CLDX - Celldex Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.62 -0.17 (-4.49 %)
(As of 04/22/2019 04:00 PM ET)
Previous Close$3.79
Today's Range$3.55 - $3.80
52-Week Range$2.74 - $12.60
Volume598,121 shs
Average Volume452,178 shs
Market Capitalization$45.03 million
P/E RatioN/A
Dividend YieldN/A
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:CLDX



Sales & Book Value

Annual Sales$9.54 million
Cash Flow$1.8756 per share
Book Value$10.78 per share


Net Income$-151,180,000.00
Net Margins-1,585.40%


Market Cap$45.03 million
Next Earnings Date5/9/2019 (Estimated)

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Shares of Celldex Therapeutics reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.20) by $0.25. The biopharmaceutical company earned $1.76 million during the quarter, compared to analyst estimates of $1.46 million. Celldex Therapeutics had a negative net margin of 1,585.40% and a negative return on equity of 53.51%. View Celldex Therapeutics' Earnings History.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Celldex Therapeutics.

What price target have analysts set for CLDX?

4 Wall Street analysts have issued twelve-month target prices for Celldex Therapeutics' shares. Their predictions range from $19.00 to $19.00. On average, they expect Celldex Therapeutics' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 424.9% from the stock's current price. View Analyst Price Targets for Celldex Therapeutics.

What is the consensus analysts' recommendation for Celldex Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celldex Therapeutics.

What are Wall Street analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:
  • 1. According to Zacks Investment Research, "Following the discontinuation of glembatumumab vedotin studies, Celldex is focused on developing its anti-cancer pipeline candidates including CDX-301, which is being developed for the lucrative lung cancer market. Celldex also has collaborations with big pharma companies, which lend solid support as well as expertise. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, the failure of glembatumumab vedotin was a major setback. With no approved products, further pipeline setbacks will severely impact Celldex. The company depends entirely on product development, licensing agreements, contracts and grants for revenues. Shares of the company have significantly underperformed the industry in the past year. Estimates movement has been mixed ahead of Q4 earnings. Celldex has a positive record of earnings surprises in the recent quarters." (2/19/2019)
  • 2. Cowen Inc analysts commented, "We are pleased with Endo’s beat and raise quarter as the company continues to pivot itself into a more specialized company with foci on durable brands like Xiaflex, specialty injectables and a specialty generic base business. As such, the strength in the shares seen post earnings likely indicates that investors are pleased with management’s recent actions (as are we). At the same time we continue to view current debt levels, ongoing opioid litigation, and legal liabilities as significant overhangs on the name that could stunt momentum and remain HOLD rated on ENDP shares." (8/9/2018)

Has Celldex Therapeutics been receiving favorable news coverage?

News articles about CLDX stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celldex Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the near term.

Who are some of Celldex Therapeutics' key competitors?

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), ACADIA Pharmaceuticals (ACAD), Micron Technology (MU), Intrexon (XON), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX) and Exelixis (EXEL).

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:
  • Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 57)
  • Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 60)
  • Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 48)
  • Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 47)
  • Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 55)

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Meditor Group Ltd (3.38%) and Virtu Financial LLC (0.21%). Company insiders that own Celldex Therapeutics stock include James J Marino and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

Which institutional investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd. View Insider Buying and Selling for Celldex Therapeutics.

Which institutional investors are buying Celldex Therapeutics stock?

CLDX stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include James J Marino and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $3.62.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $45.03 million and generates $9.54 million in revenue each year. The biopharmaceutical company earns $-151,180,000.00 in net income (profit) each year or ($6.82) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]

MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  488 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  772
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by Staff

Featured Article: Beta

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel